12 results
PCI in Acute MI with Cardiogenic Shock. #EBM #Cardiology #CULPRITSHOCK #PCI #VisualAbstract #NEJM
PCI in Acute MI ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... VisualAbstract #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Osimertinib #NSCLC ... #Survival #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction (VALIDATE-SWEDEHEART) #EBM #Cardiology #VALIDATE #SWEDEHEART #Bivalirudin #Heparin #PCI #VisualAbstract
VALIDATE-SWEDEHEART) #EBM ... Bivalirudin #Heparin #PCI ... VisualAbstract #NEJM
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock - Event Rates of the
PCI Strategies in ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... #cardiogenic #NEJM
Event Rates of the Primary End Point and Its Components at 30 Days #EBM #Cardiology #CULPRIT-SHOCK
Components at 30 Days #EBM ... #CULPRITSHOCK #PCI ... #cardiogenic #NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI trial) - Shown is
Dabigatran after PCI ... Fibrillation (RE-DUAL PCI ... warfarin (Panel A) #EBM ... TripleTherapy #PCI ... AtrialFibrillation #NEJM
Rate of Survival and the Risk of Death at 90 Days, According to Subgroup #EBM #PCC
According to Subgroup #EBM ... #PCC #ADRENAL # ... #SepticShock #NEJM
Associations between Total Mucin Concentrations and Phlegm Production and Disease Severity in Chronic Obstructive Pulmonary Disease
#EBM #Pathophys ... #PCC #Bronchitis ... ChronicBronchitis #Mucin #NEJM